1-2 of 2
Steven Zeldenrust, MD, PhD
Close
Sort by
Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease

Martha Lacy, MD, Sumithra Mandrekar, PhD, Morie Abraham A Gertz, MD, Suzanne R. Hayman, MD, Kristen Detweiler Short, RN, CNP, Francis Buadi, MD, Angela Dispenzieri, M.D., Shaji Kumar, MD, Steven Zeldenrust, MD, PhD, David Dingli, M.D., Ph.D., Philip R. Greipp, MD, John Lust, MD, PhD, Stephen Russell, MD, PhD, Robert Kyle, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Vivek Roy, MD, A. Keith Stewart, MD, Jacob Allred, Kristina Laumann, Craig B. Reeder, MD, S. Vincent Rajkumar, MD, Joseph R. Mikhael, MD
Journal: Blood
Blood (2010) 116 (21): 863.
https://doi.org/10.1182/blood.V116.21.863.863
Published: 2010
Journal Articles

Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.

Grzegorz S. Nowakowski, MD, Chin-Yang Li, MD, David Dingli, MD, PhD, Shaji Kumar, MD, Morie A. Gertz, MD, Martha Q. Lacy, MD, John A. Last, MD, Angela Dispenzieri, MD, Philip R. Greipp, MD, Steven Zeldenrust, MD, PhD, Francis Buadi, MD, Suzanne Hayman, MD, Robert A. Kyle, MD, Vincent S. Rajkumar, MD
Journal: Blood
Blood (2007) 110 (11): 1492.
https://doi.org/10.1182/blood.V110.11.1492.1492
Published: 2007